{
  "main_header": {
    "sid": 10039294,
    "name": "Medicamen Organ.",
    "stock_name": "Medicamen Organ.",
    "full_name": "Medicamen Organics Ltd",
    "name_url": "stocks-analysis/medicamen-organ",
    "exchange": 1,
    "exchangecode": "",
    "country_id": 34,
    "currency": "INR",
    "cmp": "26.95",
    "chg": "0.00",
    "chgp": "0.00%",
    "dir": 0,
    "prev_price": "26.95",
    "mcapval": "32.00 Cr",
    "mcap": "Micro Cap",
    "scripcode": "",
    "symbol": "MEDIORG",
    "ind_name": "Pharmaceuticals & Biotechnology",
    "ind_code": 4,
    "indexname": "",
    "isin": "INE0PE401018",
    "curr_date": "Dec 05",
    "curr_time": "",
    "bse_nse_vol": 8000,
    "exc_status": "Active",
    "traded_date": "Dec 05, 2025",
    "traded_date_str": "2025 12 05",
    "score": "",
    "scoreText": "",
    "Live": 0,
    "market_time": 0,
    "is_blur": 1,
    "is_blur_class": "blur-register-score-header",
    "is_blur_url": "https://www.marketsmojo.com/mojofeed/register?redirect=/stocks-analysis/medicamen-organ-10039294-1&utm_source=Spage_Header_Score",
    "mojoone": {
      "ismore": 0
    }
  },
  "news": {
    "results": [
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3745687",
        "imagepath": "",
        "date": "2025-12-04 08:47:14",
        "description": "    <div class=\"article-news-new\">\n        <div class=\"article-container\">\n\n<div class=\"article-content\">\n\n<p><strong>Current Valuation Metrics Indicate Attractiveness</strong></p>\n<p>Medicamen Organ. trades at a price-to-earnings (PE) ratio of approximately 9.6, which is notably low compared to many of its pharmaceutical peers. Its price-to-book value stands near 1.02, suggesting the stock is priced close to its net asset value. The enterprise value (EV) to EBITDA ratio of 7.9 further supports the notion of an attractively valued stock, especially when benchmarked against sector averages.</p>\n<p>Return on capital employed (ROCE) and return on equity (ROE) are healthy at 11.1% and 10.6% respectively, indicating efficient utilisation of capital and shareholder funds. These profitability metrics, combined with modest valuation multiples, suggest that the company is not overpriced relative to its earnings and ..."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3716797",
        "imagepath": "",
        "date": "2025-11-20 08:07:45",
        "description": "As of 19 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.80, an EV to EBITDA of 8.02, and a Price to Book Value of 1.04. These ratios suggest that the stock is trading at a significant discount compared to its earnings and assets.\n\nIn comparison to its peers, Medicamen Organ. stands out with a much lower PE ratio than Sun Pharma. Industries at 37.07 and Divi's Lab at 68.85, both of which are classified as expensive. Additionally, while Cipla and Dr. Reddy's Labs are also attractive, their PE ratios of 22.64 and 18.06, respectively, are still considerably higher than that of Medicamen. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -49.17% compared to the Sensex's 10.18%, reinforcing the notion tha..."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3713674",
        "imagepath": "",
        "date": "2025-11-19 08:10:48",
        "description": "As of 18 November 2025, the valuation grade for Medicamen Organ. has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 10.32, an EV to EBITDA of 8.33, and a ROCE of 11.09%. In comparison to its peers, Sun Pharma. is considered expensive with a PE ratio of 36.56, while Cipla is attractive with a PE ratio of 22.49.\n\nDespite its fair valuation, Medicamen Organ. has underperformed significantly, with a year-to-date return of -46.47% compared to a 9.58% return for the Sensex. This underperformance highlights the potential concerns surrounding the company's growth prospects relative to its peers in the pharmaceuticals and biotechnology sector...."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3710005",
        "imagepath": "",
        "date": "2025-11-18 08:26:42",
        "description": "As of 17 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade. The company appears to be undervalued, particularly when considering its key ratios: a PE ratio of 9.84, an EV to EBITDA of 7.39, and a ROCE of 12.71%. In comparison to its peers, Medicamen's valuation is significantly lower than Sun Pharma's PE ratio of 36.69 and Divi's Lab's PE ratio of 69.78, which are categorized as very expensive.\n\nDespite the attractive valuation, Medicamen has faced substantial stock declines, with a year-to-date return of -48.98%, contrasting sharply with the Sensex's positive return of 10.02%. This divergence suggests that the market may not fully recognize the company's potential, reinforcing the conclusion that Medicamen Organ. is undervalued in the current market environment...."
      },
      {
        "title": "How has been the historical performance of Medicamen Organ.?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/how-has-been-the-historical-performance-of-medicamen-organ-3704343",
        "imagepath": "",
        "date": "2025-11-15 00:34:56",
        "description": "Answer:\nThe historical performance of Medicamen Organ shows significant growth in various financial metrics from March 2024 to March 2025.\n\nBreakdown:\nMedicamen Organ's net sales increased from 25.27 Cr in March 2024 to 38.19 Cr in March 2025, contributing to a total operating income rise to 38.19 Cr from 25.27 Cr. The company's total expenditure also grew, reaching 31.60 Cr from 20.53 Cr, primarily driven by higher raw material costs, which rose to 22.25 Cr from 14.40 Cr. Operating profit (PBDIT) improved to 6.69 Cr from 5.81 Cr, although the operating profit margin decreased slightly to 17.26% from 18.76%. Profit before tax increased to 5.43 Cr from 4.44 Cr, leading to a profit after tax of 4.05 Cr, up from 2.62 Cr. The company's earnings per share rose to 3.46 from 3.05, while the book value per share increased to 25.11 from 17.74. On the balance sheet, total assets grew to 59.21 Cr from 38.44 Cr, with t..."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3696184",
        "imagepath": "",
        "date": "2025-11-13 08:12:28",
        "description": "As of 12 November 2025, the valuation grade for Medicamen Organ has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 10.36, an EV to EBIT ratio of 8.88, and an ROCE of 12.71%. In comparison to its peers, Sun Pharma is considered expensive with a PE ratio of 35.94, while Cipla is attractive with a PE ratio of 22.56.\n\nDespite the fair valuation, Medicamen Organ has experienced significant underperformance, with a year-to-date stock return of -46.29% compared to a Sensex return of 9.44%. This stark contrast highlights the potential concerns surrounding the company's market position and growth prospects within the pharmaceuticals and biotechnology sector...."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3687835",
        "imagepath": "",
        "date": "2025-11-11 08:14:34",
        "description": "As of 10 November 2025, the valuation grade for Medicamen Organ. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 10.23, an EV to EBIT of 8.80, and a ROCE of 12.71%. \n\nIn comparison to its peers, Medicamen Organ. stands out with a PE ratio that is significantly lower than Sun Pharma's 35.15 and Divi's Lab's 71.55, both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 7.63 is more favorable than the industry average, suggesting a reasonable valuation relative to its earnings potential. Recent stock performance has been underwhelming, with a year-to-date return of -46.94%, contrasting sharply with the Sensex's gain of 8.16%, further emphasizing the current valuation context...."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3674274",
        "imagepath": "",
        "date": "2025-11-06 08:10:40",
        "description": "As of 4 November 2025, Medicamen Organ. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 11.91, an EV to EBITDA of 8.62, and a ROCE of 12.71%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.41, while Cipla, which is rated attractive, has a PE ratio of 22.35.\n\nThe valuation metrics suggest that Medicamen Organ. is trading at a premium relative to its financial performance, especially when compared to peers like Dr. Reddy's Labs, which has a PE ratio of 17.36 and is rated attractive. Additionally, the company's stock has underperformed the Sensex significantly, with a year-to-date return of -38.22% compared to the Sensex's gain of 8.26%. This further reinforces the conclusion that Medicamen Organ. is currently overvalued in the market...."
      },
      {
        "title": "Is Medicamen Organ. overvalued or undervalued?",
        "link": "https://www.marketsmojo.com/news/stocks-in-action/is-medicamen-organ-overvalued-or-undervalued-3672953",
        "imagepath": "",
        "date": "2025-11-05 08:09:48",
        "description": "As of 4 November 2025, Medicamen Organ. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its financial ratios and peer comparisons. Key ratios include a PE Ratio of 11.91, an EV to EBIT of 9.94, and a Price to Book Value of 1.34, which do not justify its current market price.\n\nIn comparison to its peers, Medicamen Organ. stands out as overvalued. For instance, Sun Pharma has a significantly higher PE Ratio of 35.41, while Cipla, which is rated attractive, has a PE Ratio of 22.35. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -38.22% compared to the Sensex's 8.26%. This underperformance reinforces the notion that Medicamen Organ. is not a favorable investment at its current valuation...."
      }
    ],
    "total": 191,
    "sid": "10039294",
    "stock_news_url": "https://www.marketsmojo.com/news/medicamen-organics-10039294"
  },
  "announcements": "",
  "corporate_actions": [
    {
      "img": "board-meeting.svg",
      "title": "BOARD MEETING",
      "msg": "<span>No</span> Upcoming Board Meetings",
      "data": []
    },
    {
      "img": "dividend.svg",
      "title": "DIVIDEND",
      "msg": "No <strong>Dividend</strong> history available",
      "data": []
    },
    {
      "img": "splits.svg",
      "title": "SPLITS",
      "msg": "No <strong>Splits</strong> history available",
      "data": []
    },
    {
      "img": "bonus.svg",
      "title": "BONUS",
      "msg": "No <strong>Bonus</strong> history available",
      "data": []
    },
    {
      "img": "rights-issues.svg",
      "title": "RIGHTS",
      "msg": "No <strong>Rights</strong> history available",
      "data": []
    }
  ]
}

News and Views

Is Medicamen Organ. overvalued or undervalued?

2025-12-04 08:47:14

Current Valuation Metrics Indicate Attractiveness

Medicamen Organ. trades at a price-to-earnings (PE) ratio of approximately 9.6, which is notably low compared to many of its pharmaceutical peers. Its price-to-book value stands near 1.02, suggesting the stock is priced close to its net asset value. The enterprise value (EV) to EBITDA ratio of 7.9 further supports the notion of an attractively valued stock, especially when benchmarked against sector averages.

Return on capital employed (ROCE) and return on equity (ROE) are healthy at 11.1% and 10.6% respectively, indicating efficient utilisation of capital and shareholder funds. These profitability metrics, combined with modest valuation multiples, suggest that the company is not overpriced relative to its earnings and ...

Read More

Is Medicamen Organ. overvalued or undervalued?

2025-11-20 08:07:45

As of 19 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade, indicating a positive shift in its perceived value. The company is currently considered undervalued, with a PE ratio of 9.80, an EV to EBITDA of 8.02, and a Price to Book Value of 1.04. These ratios suggest that the stock is trading at a significant discount compared to its earnings and assets. In comparison to its peers, Medicamen Organ. stands out with a much lower PE ratio than Sun Pharma. Industries at 37.07 and Divi's Lab at 68.85, both of which are classified as expensive. Additionally, while Cipla and Dr. Reddy's Labs are also attractive, their PE ratios of 22.64 and 18.06, respectively, are still considerably higher than that of Medicamen. The company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -49.17% compared to the Sensex's 10.18%, reinforcing the notion tha...

Read More

Is Medicamen Organ. overvalued or undervalued?

2025-11-19 08:10:48

As of 18 November 2025, the valuation grade for Medicamen Organ. has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 10.32, an EV to EBITDA of 8.33, and a ROCE of 11.09%. In comparison to its peers, Sun Pharma. is considered expensive with a PE ratio of 36.56, while Cipla is attractive with a PE ratio of 22.49. Despite its fair valuation, Medicamen Organ. has underperformed significantly, with a year-to-date return of -46.47% compared to a 9.58% return for the Sensex. This underperformance highlights the potential concerns surrounding the company's growth prospects relative to its peers in the pharmaceuticals and biotechnology sector....

Read More

Is Medicamen Organ. overvalued or undervalued?

2025-11-18 08:26:42

As of 17 November 2025, Medicamen Organ. has moved from a fair to an attractive valuation grade. The company appears to be undervalued, particularly when considering its key ratios: a PE ratio of 9.84, an EV to EBITDA of 7.39, and a ROCE of 12.71%. In comparison to its peers, Medicamen's valuation is significantly lower than Sun Pharma's PE ratio of 36.69 and Divi's Lab's PE ratio of 69.78, which are categorized as very expensive. Despite the attractive valuation, Medicamen has faced substantial stock declines, with a year-to-date return of -48.98%, contrasting sharply with the Sensex's positive return of 10.02%. This divergence suggests that the market may not fully recognize the company's potential, reinforcing the conclusion that Medicamen Organ. is undervalued in the current market environment....

Read More

How has been the historical performance of Medicamen Organ.?

2025-11-15 00:34:56

Answer: The historical performance of Medicamen Organ shows significant growth in various financial metrics from March 2024 to March 2025. Breakdown: Medicamen Organ's net sales increased from 25.27 Cr in March 2024 to 38.19 Cr in March 2025, contributing to a total operating income rise to 38.19 Cr from 25.27 Cr. The company's total expenditure also grew, reaching 31.60 Cr from 20.53 Cr, primarily driven by higher raw material costs, which rose to 22.25 Cr from 14.40 Cr. Operating profit (PBDIT) improved to 6.69 Cr from 5.81 Cr, although the operating profit margin decreased slightly to 17.26% from 18.76%. Profit before tax increased to 5.43 Cr from 4.44 Cr, leading to a profit after tax of 4.05 Cr, up from 2.62 Cr. The company's earnings per share rose to 3.46 from 3.05, while the book value per share increased to 25.11 from 17.74. On the balance sheet, total assets grew to 59.21 Cr from 38.44 Cr, with t...

Read More

Is Medicamen Organ. overvalued or undervalued?

2025-11-13 08:12:28

As of 12 November 2025, the valuation grade for Medicamen Organ has moved from attractive to fair. The company is currently fairly valued, with a PE ratio of 10.36, an EV to EBIT ratio of 8.88, and an ROCE of 12.71%. In comparison to its peers, Sun Pharma is considered expensive with a PE ratio of 35.94, while Cipla is attractive with a PE ratio of 22.56. Despite the fair valuation, Medicamen Organ has experienced significant underperformance, with a year-to-date stock return of -46.29% compared to a Sensex return of 9.44%. This stark contrast highlights the potential concerns surrounding the company's market position and growth prospects within the pharmaceuticals and biotechnology sector....

Read More

Is Medicamen Organ. overvalued or undervalued?

2025-11-11 08:14:34

As of 10 November 2025, the valuation grade for Medicamen Organ. has moved from expensive to fair. The company is currently fairly valued based on its financial metrics. Key ratios include a PE ratio of 10.23, an EV to EBIT of 8.80, and a ROCE of 12.71%. In comparison to its peers, Medicamen Organ. stands out with a PE ratio that is significantly lower than Sun Pharma's 35.15 and Divi's Lab's 71.55, both of which are categorized as expensive. Additionally, its EV to EBITDA ratio of 7.63 is more favorable than the industry average, suggesting a reasonable valuation relative to its earnings potential. Recent stock performance has been underwhelming, with a year-to-date return of -46.94%, contrasting sharply with the Sensex's gain of 8.16%, further emphasizing the current valuation context....

Read More

Is Medicamen Organ. overvalued or undervalued?

2025-11-06 08:10:40

As of 4 November 2025, Medicamen Organ. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its key financial ratios, including a PE ratio of 11.91, an EV to EBITDA of 8.62, and a ROCE of 12.71%. In comparison to its peers, Sun Pharma has a significantly higher PE ratio of 35.41, while Cipla, which is rated attractive, has a PE ratio of 22.35. The valuation metrics suggest that Medicamen Organ. is trading at a premium relative to its financial performance, especially when compared to peers like Dr. Reddy's Labs, which has a PE ratio of 17.36 and is rated attractive. Additionally, the company's stock has underperformed the Sensex significantly, with a year-to-date return of -38.22% compared to the Sensex's gain of 8.26%. This further reinforces the conclusion that Medicamen Organ. is currently overvalued in the market....

Read More

Is Medicamen Organ. overvalued or undervalued?

2025-11-05 08:09:48

As of 4 November 2025, Medicamen Organ. has moved from a fair to an expensive valuation grade. The company is currently considered overvalued based on its financial ratios and peer comparisons. Key ratios include a PE Ratio of 11.91, an EV to EBIT of 9.94, and a Price to Book Value of 1.34, which do not justify its current market price. In comparison to its peers, Medicamen Organ. stands out as overvalued. For instance, Sun Pharma has a significantly higher PE Ratio of 35.41, while Cipla, which is rated attractive, has a PE Ratio of 22.35. Furthermore, the company's recent stock performance has lagged behind the Sensex, with a year-to-date return of -38.22% compared to the Sensex's 8.26%. This underperformance reinforces the notion that Medicamen Organ. is not a favorable investment at its current valuation....

Read More

View All News